BioMarin Reports Positive Phase 3 Results For VOXZOGO
(RTTNews) - BioMarin Pharmaceutical Inc. (BMRN) on Wednesday announced positive Phase 3 results for VOXZOGO (vosoritide) in children with hypochondroplasia, with the study meeting its primary endpoint and all secondary efficacy endpoints.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.